US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029

2.1 Approved Transdermal Patches Insight
2.2 Current Market Scenario
2.3 Favorable Market Growth Inhibitors
2.4 Clinical & Commercialization Challenges
2.5 Future Marketing Opportunities

4.1 Brain, Neurological & Psychotic Disorders
4.2 Hormone Modulators
4.2.1 Hormone Replacement Therapies (HRT)
4.2.2 Contraception
4.3 Diabetes
4.4 Vaccine
4.5 Substance Use Disorders
4.6 Cardiovascular Diseases

5.1 By Company
5.2 By Drug Class
5.3 By Indication
5.4 By Phase
5.5 By Priority Status

6.1 Clonidine Transdermal Patch
6.2 Nitroglycerin Transdermal Patch

7.1 Fentanyl Transdermal Patch
7.2 Buprenorphine Transdermal Patch

8.1 Selegiline Transdermal Patch
8.2 Rivastigmine Transdermal Patch
8.3 Methylphenidate Transdermal Patch
8.4 Asenapine Transdermal Patch
8.5 Rotigotine Transdermal Patch (Neupro) sales
8.6 Donepezil Transdermal Patch
8.7 Dextroamphetamine Transdermal Patch

9.1 Estradiol Transdermal Patch
9.2 Testosterone Transdermal Patch (Androderm)

10.1 Nicotine Transdermal Patch
10.2 Oxybutynin Transdermal Patch
10.3 Granisetron Transdermal Patch (Sancuso)

11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-II
11.5 Phase-III
11.6 Preregistration
11.7 Registered

13.1 AbbVie
13.2 AFYX Therapeutics
13.3 Agile Therapeutics
13.4 Bayer HealthCare Pharmaceuticals
13.5 Corsair Pharma
13.6 DBV Technologies
13.7 Hisamitsu Pharmaceutical
13.8 IBSA
13.9 Privo Technologies
13.10 Psilera
13.11 Starton Therapeutics
13.12 Teikoku Pharma USA
13.13 Teikoku Seiyaku
13.14 UCB
13.15 Vaxess Technologiess
13.16 Verndari

Figure 2.1: Advantages of Transdermal Patches
Figure 2.2: Disadvantages of Transdermal Patches
Figure 2.3: US - Transdermal Patch Market (US$ Billion), 2021-2029
Figure 2.4: Transdermal Patch Market Favorable Factors
Figure 2.5: Transdermal Patch Market Commercialization Challenges
Figure 3.1: Nitroglycerin - Branded v/s Generic Version Costs for Different Doses (US$), September 2023
Figure 3.2: Nitroglycerin - Branded v/s Generic Version Percentage Decrease in Cost, September 2023
Figure 3.3: Implications of Branded vs Generic Competition
Figure 4.1: Potential Market Segments of Transdermal Drug Delivery Systems
Figure 4.2: NCT03740204 Phase 2 Study - Initiation & Completion Years
Figure 4.3: DepMIND3 Phase 2 Study - Initiation & Completion Years
Figure 4.4: NCT05704036 Phase 2 Study - Initiation & Completion Years
Figure 4.5: NCT03875378 Phase 2 Study - Initiation & Completion Years
Figure 4.6: Requirements of Female Contraceptive Transdermal Patches
Figure 4.7: Benefits of Female Contraceptive Transdermal Drug Delivery System
Figure 4.8: Benefits of Insulin Transdermal Patch
Figure 4.9: Drawbacks of Insulin Transdermal Patch
Figure 4.10: Benefits of Vaccine Transdermal Patch
Figure 4.11: Drawbacks of Vaccine Transdermal Patch
Figure 4.12: Factors Responsible for Increased Consumption of Nicotine Patches
Figure 4.13: NCT05886582 Phase 2 Study - Initiation & Completion Years
Figure 5.1: US - Transdermal Patch Pipeline by Company (Numbers), 2023 till 2029
Figure 5.2: US Transdermal Patch Pipeline by Drug Class (Numbers), 2023 till 2029
Figure 5.3: US Transdermal Patch Pipeline by Indication (Numbers), 2023 till 2029
Figure 5.4: US Transdermal Patch Pipeline by Phase (Numbers), 2023 till 2029
Figure 5.5: US Transdermal Patch Pipeline by Priority Status (Numbers), 2023 till 2029
Figure 6.1: Catapres - FDA Approval, First Generic Approval & Branded Drug Discontinuation Years
Figure 6.2: Generic Clonidine Patch - Price per Unit & Supply of Different Doses (US$), September 2023
Figure 6.3: Clonidine Transdermal Patch - Recommended Initial, Incremented & Maximum Doses (mg/week)
Figure 6.4: Clonidine Transdermal Patch - Monthly & Annual Treatment Costs (US$), September 2023
Figure 6.5: Nitro-Dur - Price per Unit & Supply of Different Doses (US$), September 2023
Figure 6.6: Generic Nitroglycerin Transdermal Patch - Price per Unit & Supply of Different Doses (US$), September 2023
Figure 7.1: Duragesic - FDA Approval, First Generic Approval & Branded Drug Discontinuation Years
Figure 7.2: Generic Fentanyl Transdermal Patch - Price per Unit & Supply of Different Doses (US$), September 2023
Figure 7.3: Butrans - Price per Unit & Supply of Different Doses (US$), September 2023
Figure 7.4: Generic Buprenorphine Transdermal Patch - Price per Unit & Supply of Different Doses (US$), September 2023
Figure 8.1: Emsam - Price per Unit & Supply (US$), September 2023
Figure 8.2: Emsam - Monthly & Annual Treatment Costs (US$), September 2023
Figure 8.3: Exelon - Price per Unit & Supply (US$), September 2023
Figure 8.4: Generic Rivastigmine Transdermal Patch - Price per Unit & Supply (US$), September 2023
Figure 8.5: Exelon - Initial & Maintenance Dose for Treatment of Parkinson’s disease
Figure 8.6: Exelon - Monthly & Annual Treatment Costs for Parkinson’s disease (US$), September 2023
Figure 8.7: US - Daytrana Patent Issue & Expiration Year
Figure 8.8: Daytrana - Price per Unit & Supply of All Doses (US$), September 2023
Figure 8.9: US - Secuado Patent Issue & Expiration Years
Figure 8.10: Secuado - Price per Unit & Supply of All Doses (US$), September 2023
Figure 8.11: Secuado - Recommended Initial & Incremented Dose (mg/Day)
Figure 8.12: US - Neupro Patent Issue & Expiration Years
Figure 8.13: Neupro - Price per Unit & Supply (US$), September 2023
Figure 8.14: Neupro - Initial & Maximum Recommended Doses for Early-Stage & Advanced Parkinson’s disease (mg/day)
Figure 8.15: Neupro - Initial & Maximum Recommended Dose for Restless Leg Syndrome (mg/day)
Figure 8.16: US - Neupro Annual Sales (US$ Million), 2019-2022
Figure 8.17: Global - Neupro Annual Sales (US$ Million), 2019-2023*
Figure 8.18: US - Adlarity Patent Issue & Expiration Years
Figure 8.19: Adlarity - Price per Unit & Supply for All Doses (US$), September 2023
Figure 8.20: Adlarity - Recommended Initial & Incremented Dose (mg/day)
Figure 8.21: Adlarity - Monthly & Yearly Treatment Costs (US$), September 2023
Figure 8.22: US - Xelstrym Patent Issue & Expiration Years
Figure 8.23: Xelstrym - Price per Unit & Supply for All Doses (US$), September 2023
Figure 8.24: Xelstrym - Recommended Initial & Maximum Doses for Pediatric & Adult Patients (mg/day)
Figure 9.1: Vivelle-Dot - FDA Branded & First Generic Approval Years
Figure 9.2: Vivelle-Dot - Price per Unit & Supply of Different Doses (US$), September 2023
Figure 9.3: Recommended Doses for Treatment of Vaginal Atrophy, Vasomotor Symptoms, & Postmenopausal Osteoporosis (mg/Day)
Figure 9.4: Minivelle - FDA Branded & First Generic Approval Years
Figure 9.5: US - Minivelle Patent Issue & Expiration YearS
Figure 9.6: Minivelle - Price per Unit & Supply of All Doses (US$), September 2023
Figure 9.7: Minivelle - Recommended Dose by Indication (mg/Day)
Figure 9.8: Climara - FDA Branded & First Generic Approval Years
Figure 9.9: Climara - Price per Unit & Supply of Various Doses (US$), September 2023
Figure 9.10: Menostar - FDA Branded & First Generic Approval Years
Figure 9.11: Menostar - Price per Unit & Supply (US$), September 2023
Figure 9.12: Climara Pro - Price per Unit & Supply (US$), September 2023
Figure 9.13: CombiPatch - Price per Unit & Supply of Both Doses (US$), September 2023
Figure 9.14: Xulane - Price per Unit & Supply (US$), September 2023
Figure 9.15: Xulane - Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 9.16: Zafemy - Price per Unit & Supply (US$), September 2023
Figure 9.17: US - Twirla Patent Issue & Expiration Year
Figure 9.18: Twirla - Price per Unit & Supply (US$), September 2023
Figure 9.19: Twirla - Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 9.20: Generic Estradiol Transdermal Patch - Price per unit & Supply (US$),  September 2023
Figure 9.21: Androderm - Price per Unit & Supply (US$), September 2023
Figure 9.22: Androderm - Recommended Initial & Maintainence Dose for Treatment of  Hypogonadism (mg/day)
Figure 10.1: Nicoderm CQ - Price per Unit & Supply of 7mg & 14mg Transdermal Patches (US$), September 2023
Figure 10.2: Nicoderm CQ - Price per Unit & Supply of 21mg Transdermal Patches  (US$), September 2023
Figure 10.3: Nicoderm CQ - Recommended Dose & Treatment Schedule for Patients  with Consumption of >10 Cigarette/Day (mg/day)
Figure 10.4: Nicoderm CQ - Recommended Dose & Treatment Schedule for Patients  with Consumption of <10 Cigarette/Day (mg/day)
Figure 10.5: Nicoderm CQ - Full Treatment Cost for Patients with Daily Consumption  of <10 Cigarettes & >10 Cigarettes (US$), September 2023
Figure 10.6: Habitrol - Price per Unit & Supply (US$), September 2023
Figure 10.7: Habitrol - Recommended Dose & Treatment Schedule for Patients with  Consumption of >10 Cigarettes/Day (mg/day)
Figure 10.8: Habitrol - Recommended Dose & Treatment Schedule for Patients with  Consumption of <10 Cigarettes/Day (mg/day)
Figure 10.9: Habitrol - Full Treatment Cost for Patients with Daily Consumption of <10  Cigarettes & >10 Cigarettes (US$), September 2023
Figure 10.10: Generic Nicotine Transdermal Patch - Price per Unit & Supply of Dose  7mg (US$), September 2023
Figure 10.11: Generic Nicotine Transdermal Patch - Price per Unit & Supply of Dose  14mg (US$), September 2023
Figure 10.12: Generic Nicotine Transdermal Patch - Price per Unit & Supply of Dose  21mg (US$), September 2023
Figure 10.13: Oxytrol - Price per Unit & Supply (US$), September 2023
Figure 10.14: Oxytrol for Women - Price per Unit & Supply (US$), September 2023
Figure 10.15: Sancuso - Patent Issue & Expiration Year

Table 2.1: US - Currently Available Branded Transdermal Patches
Table 2.2: Features Required in Transdermal Patches
Table 3.1: Comparison of Features of Branded & Generic Patches
Table 7.1: Butrans - Initial Dose Calculation using Previous Opioid (Morphine) Dosage
Table 8.1: Daytrana - Recommended Titration Schedule for ADHD Treatment